Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 18 (1), 2-7

Helicobacter Pylori in Iran: A Systematic Review on the Antibiotic Resistance


Helicobacter Pylori in Iran: A Systematic Review on the Antibiotic Resistance

Farzad Khademi et al. Iran J Basic Med Sci.


Objectives: Helicobacter pylori (H. pylori) is a pathogenic bacterium that colonizes the stomachs of approximately 50% of the world's population. Resistance of H. pylori to antibiotics is considered as the main reason for the failure to eradicate this bacterium. The aim of this study was to determine the rate of resistant H. pylori strains to various antimicrobial agents in different areas of Iran.

Materials and methods: A systematic review of literatures on H. pylori antibiotic resistance in Iran was performed within the time span of 1997 to 2013. Data obtained from various studies were tabulated as following, 1) year of research and number strains tested, 2) number of H. pylori positive patients, 3) study place, 4) resistance of H. pylori to various antibiotics as percentage, and 5) methods used for evaluation of antibiotic resistance.

Results: Over the period, a total of 21 studies on H. pylori antibiotic resistance have been conducted in different parts of Iran. In these studies, H. pylori resistance to various antibiotics, including metronidazole, clarithromycin, amoxicillin, tetracycline, ciprofloxacin, levofloxacin and furazolidone were 61.6%, 22.4%, 16.0%, 12.2%, 21.0%, 5.3% and 21.6%, respectively. We found no study on H. pylori resistance to rifabutin in Iran.

Conclusion: Compared to the global average, we noted that the prevalence of H. pylori resistance to metronidazole, clarithromycin, amoxicillin, and tetracycline has been rapidly growing in Iran. This study showed that in order to determine an appropriate drug regimen against H. pylori, information on antibiotic susceptibility of the bacterium within different geographical areas of Iran is required.

Keywords: Antibiotic resistance; Helicobacter pylori; Iran.

Conflict of interest statement

Conflicts of interest

This plan does not have any financial burden, and there is no conflict of interest.


Figure 1
Figure 1
Status of Helicobacter pylori antibiotic resistance in Iran MTZ-metronidazole; CLA-clarithromycin; AMO-amoxycillin; TET-tetracycline; LEV-levofloxacin; RIF-rifabutin; FRZ-furazolidone; CIP-ciprofloxaci

Similar articles

See all similar articles

Cited by 22 PubMed Central articles

See all "Cited by" articles


    1. Hosseini E, Poursina F, Van de Wiele T, Safaei HG, Adibi P. Helicobacter pylori in Iran: A systematic review on the association of genotypes and gastroduodenal diseases. J Res Med Sci. 2012;17:280–292. - PMC - PubMed
    1. Tanih NF, Clarke AM, Mkwetshana N, Green E, Ndip LM, Ndip RN. Helicobacter pylori infection in Africa: Pathology and microbiological diagnosis. Afr J Biotechnol. 2008;7:4653–4662.
    1. Jones KR, Cha J-H, Merrell DS. Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori. Curr Drug ther. 2008;3:190–203. - PMC - PubMed
    1. Rimbara E, Noguchi N, Kijima H, Yamaguchi T, Kawai T, Sasatsu M. Mutations in the 23S rRNA gene of clarithromycin-resistant Helicobacter pylori from Japan. Int J Antimicrob Agents. 2007;30:250–4. - PubMed
    1. Beswick EJ, Suarez G, Reyes VE. Helicobacter pylori and host interactions that influence pathogenesis. World J Gastroenterol. 2006;12:5599–5605. - PMC - PubMed

LinkOut - more resources